Supplementary material for the article:

Cvijetić, I. N.; Verbić, T. Ž.; Ernesto de Resende, P.; Stapleton, P.; Gibbons, S.; Juranić, I. O.; Drakulić, B. J.; Zloh, M. Design, Synthesis and Biological Evaluation of Novel Aryldiketo Acids with Enhanced Antibacterial Activity against Multidrug Resistant Bacterial Strains. *European Journal of Medicinal Chemistry* **2018**, *143*, 1474–1488. https://doi.org/10.1016/j.ejmech.2017.10.045

Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains

Ilija N. Cvijetić^{1*}, Tatjana Ž. Verbić², Pedro Ernesto de Resende³, Paul Stapleton³, Simon Gibbons³, Ivan O. Juranić⁴, Branko J. Drakulić^{4†}, Mire Zloh^{5*}

¹Innovation center of the Faculty of Chemistry, University of Belgrade, Studentski trg 16, Belgrade, Serbia

²Faculty of Chemistry, University of Belgrade, Studentski trg 16, Belgrade, Serbia

³UCL School of Pharmacy, University College London, London, UK

⁴Institute of Chemistry, Technology and Metallurgy, Department of Chemistry, University of Belgrade, Njegoševa 12, Belgrade, Serbia

⁵University of Hertfordshire, College Lane, Hatfield, AL10 9AB, UK

^{*}Corresponding authors: <u>zloh@live.co.uk</u> and <u>ilija@chem.bg.ac.rs</u>

[†] Authors regret to inform that Branko Drakulić has passed away since completion of the research for this paper.

NMR spectra




Figure S1. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-2-hydroxy-4-oxo-4-(*o*-tolyl)but-2-enoic acid (2).




Figure S2. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-2-hydroxy-4-oxo-4-(*m*-tolyl)but-2-enoic acid (3).




Figure S3. 1D 1 H and 1D 13 C NMR spectra of (Z)-4-(4-butylphenyl)-2-hydroxy-4-oxobut-2-enoic acid (4).




Figure S4. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-4-(2,4-dimethylphenyl)-2-hydroxy-4-oxobut-2-enoic acid (5).




Figure S5. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-2-hydroxy-4-oxo-4-(2,4,5-trimethylphenyl)but-2-enoic acid (6).




Figure S6. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-2-hydroxy-4-oxo-4-(2,3,5,6-tetramethylphenyl)but-2-enoic acid (7).






Figure S7. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-2-hydroxy-4-oxo-4-(5,6,7,8-tetrahydronaphthalen-2-yl)but-2-enoic acid (8).




Figure S8. 1D ¹H and 1D ¹³C NMR spectra of 1-(4-ethyl-2,6-diisopropylphenyl)ethanone (**5a**).




Figure S9. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-2-hydroxy-4-oxo-4-(2,4,6-triisopropylphenyl)but-2-enoic acid (**9**).




Figure S10. 1D 1 H and 1D 13 C NMR spectra of 4-oxo-4-(2,4,6-triisopropylphenyl) butanoic acid (2a).




Figure S11. 1D ¹H and 1D ¹³C NMR spectra of 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid (3a).




Figure S12. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-2-hydroxy-4-(4-methoxy-2,5-dimethylphenyl)-4-oxobut-2-enoic acid (**10**).




Figure S13. 1D 1 H NMR spectrum of (*Z*)-2-hydroxy-4-(4-hydroxy-3,5-dimethylphenyl)-4-oxobut-2-enoic acid (**11**).




Figure S14. 1D ¹H spectrum of 1-(2,5-dicyclohexylphenyl)ethanone (**4a**).




Figure S15. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-4-(2,5-dicyclohexylphenyl)-2-hydroxy-4-oxobut-2-enoic acid (**12**).




Figure S16. 1D ¹H NMR spectrum of 4-(2,5-dicyclohexylphenyl)-4-oxobutanoic acid (1a).




Figure S17. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-2-hydroxy-4-(2-methoxyphenyl)-4-oxobut-2-enoic acid (13).




Figure S18. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-2-hydroxy-4-(3-methoxyphenyl)-4-oxobut-2-enoic acid (14).




Figure S19. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-4-(3-bromophenyl)-2-hydroxy-4-oxobut-2-enoic acid (15).




Figure S20. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-2-hydroxy-4-oxo-4-(3-(trifluoromethyl)phenyl)but-2-enoic acid (**16**).




Figure S21. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-2-hydroxy-4-oxo-4-(4-(pyrrolidin-1-yl)phenyl)but-2-enoic acid (**17**).




Figure S22. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-2-hydroxy-4-(4-morpholinophenyl)-4-oxobut-2-enoic acid (**18**).






Figure S23. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-4-(4-(1*H*-imidazol-1-yl)phenyl)-2-hydroxy-4-oxobut-2-enoic acid (**19**).




Figure S24. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-2-hydroxy-4-(4-(4-methylpiperazin-1-yl)phenyl)-4-oxobut-2-enoic acid (**20**).




Figure S25. 1D 1 H and 1D 13 C NMR spectra of (*Z*)-4-(4-(dimethylamino)phenyl)-2-hydroxy-4-oxobut-2-enoic acid (**21**).




Figure S26. Changes in fluorescence emission spectra of HSA ($c = 0.5 \mu M$) upon addition of comp. **12** ($c_{12} = 0.0; 0.25; 0.5; 0.75; 1; 1.5; 2.0; 3.0; 4.0 \mu M); <math>T = 293 \text{ K}$, left; T = 313 K, right; 30 mM PBS, pH = 7.38.